E. Louis, A. Collard, A. Oger, E. Degroote, F. Yafi et al., Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease, Gut, vol.49, issue.6, pp.777-82, 2001.
DOI : 10.1136/gut.49.6.777

E. Langholz, P. Mukholm, M. Davidsen, O. Nielsen, and V. Binder, Changes in Extent of Ulcerative Colitis A Study on the Course and Prognostic Factors, Scandinavian Journal of Gastroenterology, vol.88, issue.3, pp.260-266, 1996.
DOI : 10.3109/00365529609004876

. Anonymous, Wihelm Fabry (1560-1624): the other Fabricius, JAMA, vol.190, p.933, 1964.

B. Crohn, L. Ginzburg, G. Oppenheimer, D. Gordon, and . Oppenheimer, Regional Ileitis, JAMA, vol.251, issue.1, pp.73-79, 1984.
DOI : 10.1001/jama.1984.03340250053024

S. Wilks, Morbid appearances in the intestine of Miss Bankes, London Medical Times & Gazette, vol.2, p.264, 1859.

L. Jr and E. , Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences, Gastoenterology, vol.126, pp.1504-1521, 2004.

C. Gower-rousseau, J. Salomez, R. Marti, M. Nuttens, and A. Votte, Incidence of inflammatory bowel disease in northern France (1988-1990)., Registre EPIMAD : enregistrement des maladies ulcéro-hémorragiques dans la région Nord-Ouest de la France, pp.1433-1441, 1988.
DOI : 10.1136/gut.35.10.1433

B. Burrill, L. Ginzburg, D. Gordon, and A. J. Oppenheimer, Iléite régionale, une entité pathologique et clinique, pp.1323-1329, 1932.

N. Nguyen, E. Torres, and M. Regueiro, Inflammatory Bowel Disease Characteristics Among African Americans, Hispanics, and Non-Hispanic Whites: Characterization of a Large North American Cohort, The American Journal of Gastroenterology, vol.77, issue.5, pp.1012-1023, 2006.
DOI : 10.1097/00054725-200403000-00005

C. Rousseau, J. Macry, J. Colombel, M. Sahbatou, and G. Thomas, Association of NOD2 leucine-rich repeat variants with susceptibility of Crohn's disease, Nature, vol.411, pp.599-603, 2001.

Y. Ogura, D. Bonen, N. Inohara, D. Nicolae, F. Chen et al., A frameshift mutation in NOD2 associated with suscepibility to Crohn's disease, Nature, vol.411, pp.537-539, 2001.

R. Russel and J. Satsangi, IBD: a family affair, Best Practice & Research Clinical Gastroenterology, vol.18, issue.3, pp.525-539, 2004.
DOI : 10.1016/j.bpg.2003.12.006

M. Orholm, V. Binder, T. Sorensen, L. Rasmussenand, and K. Kyvik, Concordance of inflammatory bowel disease among Danish twins: results of a nationwide study, Scand J Gastroenterol, vol.35, pp.1075-1081, 2000.

J. Hampe, K. Heymann, M. Krawczak, and S. Scchreiber, Association of inflammatory bowel disease with indicators for childhood antigen and infection exposure, International Journal of Colorectal Disease, vol.18, issue.5, pp.413-417, 2003.
DOI : 10.1007/s00384-003-0484-1

J. Mawdsley and D. Rampton, Psychological stress in IBD: new insights into pathogenic and therapeutic implications, Gut, vol.54, issue.10, pp.1-16, 2005.
DOI : 10.1136/gut.2005.064261

R. Andersson, G. Olaison, C. Tysk, and A. Elbom, Appendectomy and Protection against Ulcerative Colitis, New England Journal of Medicine, vol.344, issue.11, pp.808-814, 2001.
DOI : 10.1056/NEJM200103153441104

W. Selby, S. Griffin, N. Abraham, and M. Salomon, Appendectomy protects against the development of ulcerative colitis but does not affect its course, The American Journal of Gastroenterology, vol.28, issue.11, pp.2834-2838, 2002.
DOI : 10.1111/j.1572-0241.2000.01680.x

J. Cosnes, P. Seksik, I. Nion-larmurier, L. Beaugerie, and J. Gendre, Prior appendectomy and the phenotype and course of Crohn???s disease, World Journal of Gastroenterology, vol.12, issue.8, pp.1235-1242, 2006.
DOI : 10.3748/wjg.v12.i8.1235

R. Andersson, G. Olaison, C. Tysk, and A. Elbom, Appendectomy is followed by increased risk of Crohn's disease, Gastroenterology, vol.124, issue.1, pp.40-46, 2003.
DOI : 10.1053/gast.2003.50021

M. Carter, A. Lobo, and S. Travis, Guidelines for the management of inflammatory bowel disease in adults, Gut, vol.53, issue.suppl_5, pp.1-16, 2004.
DOI : 10.1136/gut.2004.043372

A. Kornbluth and D. Sachar, Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee, The American Journal of Gastroenterology, vol.124, issue.7, pp.1371-1385, 2004.
DOI : 10.1016/j.gastro.2003.08.023

A. Konrad, C. Rutten, B. Flogerzi, M. Styner, B. Goke et al., Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients, Am J Gastroenterol, vol.99, pp.432-441, 2004.

E. Telemo, M. Korotkova, and L. Hanson, Immune sensitization to yeast antigens in ASCA-positive patients with Crohn's disease, Inflamm Bowel Dis, vol.10, pp.97-105, 2004.

M. Baudrand and B. Bonaz, Pharmacie clinique et thérapeutique : traitement de la recto-colite ulcéro-hémorragique et de la maladie de Crohn, pp.247-64, 2008.

H. Jayaram, J. Satsangi, and R. Chapman, Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: fact or fiction?, Gut, vol.48, issue.3, pp.430-434, 2001.
DOI : 10.1136/gut.48.3.430

C. Bernstein, J. Blanchard, E. Kliewer, and A. Wajd, Cancer risk in patients with inflammatory bowel disease, Cancer, vol.77, issue.4, pp.854-862, 2001.
DOI : 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z

S. Itzkowitz and D. Present, Crohn's disease Colitis Foundation of American Colon Cancer in IBDSG. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease, Inflamm Bowel Dis &&, vol.2005, pp.314-321

V. Palascak-juif, A. Bouvier, and J. Cosnes, Small Bowel Adenocarcinoma in Patients with Crohn??s Disease Compared with Small Bowel Adenocarcinoma De Novo, Inflammatory Bowel Diseases, vol.11, issue.9, pp.828-832, 2005.
DOI : 10.1097/01.mib.0000179211.03650.b6

L. Beaugerie, N. Brousse, . Bouvier, J. Colombel, M. Lémann et al., Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study, The Lancet, vol.374, issue.9701, pp.1617-1625, 2009.
DOI : 10.1016/S0140-6736(09)61302-7

URL : https://hal.archives-ouvertes.fr/hal-00466312

J. Colombel, P. Rutgeerts, and W. Reinisch, P087 - SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy, Journal of Crohn's and Colitis, vol.3, issue.1, 2008.
DOI : 10.1016/S1873-9946(09)60114-8

D. Hommes, F. Baert, G. Van-assche, F. Caenepeel, P. Vergauwe et al., Early combined immunosuppression or conventional managemement in patients with newly diagnosed Crohn's disease: an open randomized trial, Lancet, vol.371, pp.660-667, 2008.

L. Beaugerie, P. Seksik, I. Nion-larmurier, J. Gendre, and J. Cosnes, Predictors of Crohn???s Disease, Gastroenterology, vol.130, issue.3, pp.650-656, 2006.
DOI : 10.1053/j.gastro.2005.12.019

S. Hanauer and U. Stromberg, Oral pentasa in the treatment of active Crohn?s disease: A meta-analysis of double-blind, placebo-controlled trials, Clinical Gastroenterology and Hepatology, vol.2, issue.5, pp.379-388, 2004.
DOI : 10.1016/S1542-3565(04)00122-3

F. Velayos, J. Terdiman, and J. Walsh, Effect of 5-Aminosalicylate Use on Colorectal Cancer and Dysplasia Risk: A Systematic Review and Metaanalysis of Observational Studies, The American Journal of Gastroenterology, vol.18, issue.2, pp.345-353, 2005.
DOI : 10.1097/00054725-200401000-00003

R. Modigliani, J. Mary, J. Simon, A. Cortot, J. Soulé et al., Clinical, biological, and endoscopic picture of attacks of Crohn's disease, Gastroenterology, vol.98, issue.4, pp.811-819, 1990.
DOI : 10.1016/0016-5085(90)90002-I

H. Bili, J. Algayres, F. Revel, G. Coutant, and J. Daly, Insuffisance surrénale aiguë après arrêt d'une corticothérapie prolongée par lavements de betnesol au cours d'une rectocolite hémorragique, Gastroenterol Clin Biol, vol.22, pp.1113-1117, 1998.
DOI : 10.1016/s0248-8663(97)81103-4

J. Cosnes, I. Nion-larmurier, L. Beaugerie, P. Afchain, E. Tiret et al., Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery, Gut, vol.54, issue.2, pp.237-278, 2005.
DOI : 10.1136/gut.2004.045294

J. Colombel, N. Ferrari, H. Debuysere, P. Marteau, J. Gendre et al., Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy, Gastroenterology, vol.118, issue.6, pp.1025-103, 2000.
DOI : 10.1016/S0016-5085(00)70354-4

X. Roblin, A. Chartier, F. Heluwaert, E. Germain, G. Bessard et al., Intérêt des dérivés méthylés dans l'obtention de la rémission clinique chez les patients atteints de maladies inflammatoires chroniques de l'intestin sous azatioprine/mercaptopurine

C. Letoublon and . Pancréatite-aigüe, Corpus médical de la faculté de médecine de Grenoble Avril, Mise à jour Mars 2005) ; Consultation, p.18, 2003.

M. Dubinsky, P. Hassard, and E. Seidman, An Open-Label Pilot Study Using Thioguanine as a Therapeutic Alternative in Crohn's Disease Patients Resistant to 6-Mercaptopurine Therapy, Inflammatory Bowel Diseases, vol.7, issue.3, pp.181-190, 2001.
DOI : 10.1097/00054725-200108000-00001

B. Bonaz, J. Boitard, M. Ph, M. Lehmann, J. Belaiche et al., La 6- thioguanine : une alternative thérapeutique à l'azathioprine dans la maladie de Crohn ?, Gastroenterol Clin Biol, vol.26, pp.2-3, 2002.

M. Dubinsky, E. Vasiliauskas, H. Singh, M. Abreu, K. Papadakis et al., 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients, Gastroenterology, vol.125, issue.2, pp.298-303, 2003.
DOI : 10.1016/S0016-5085(03)00938-7

S. Lichtiger, D. Present, and A. Kornbluth, Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy, New England Journal of Medicine, vol.330, issue.26, pp.1841-1886, 1994.
DOI : 10.1056/NEJM199406303302601

F. Anderson, M. Rowe, J. H. , W. Phd, L. C. Karp et al., Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis, Am J Gastroenterol, vol.95, pp.2000-2008, 2000.

B. Feagan, J. Mcdonald, and J. Rochon, Low-Dose Cyclosporine for the Treatment of Crohn's Disease, New England Journal of Medicine, vol.330, issue.26, pp.1846-1851, 1994.
DOI : 10.1056/NEJM199406303302602

G. Van-assche, D. Haens, G. Noman, and M. , Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D???Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial management, data analysis, and writing the paper. Maja Noman had a major contribution in the clinical ambulatory follow-up of the patients in the trial. Martin Hiele followed cyclosporine levels and adjusted drug doses of patients in the trial and provided statistical advice. Katrien Asnong was the study coordinator and had a major share in data analysis. Joris Arts analyzed safety data and followed patients clinically during the trial. Andre D???Hoore and Freddy Penninckx performed the surgical interventions in patients failing the trial and substantially contributed in evaluating patients for colectomy., Gastroenterology, vol.125, issue.4, pp.1025-1056, 2003.
DOI : 10.1016/S0016-5085(03)01214-9

N. Haslam, S. D. Hearing, and C. S. Probert, Audit of cyclosporin use in inflammatory bowel disease, European Journal of Gastroenterology & Hepatology, vol.12, issue.6, pp.657-60, 2000.
DOI : 10.1097/00042737-200012060-00015

D. A. Schwartz, M. , W. J. Sandborn, D. Md, . Gastroenterology et al., Treatment of Perianal Crohn's Disease: State of the Art

D. Chow and R. Leong, The use of tacrolimus in the treatment of inflammatory bowel disease, Expert Opinion on Drug Safety, vol.95, issue.5, pp.1860-1866, 1998.
DOI : 10.1056/NEJMoa020888

T. Tan, C. Lawrance, and I. , Use of mycophenolate mofetil in inflammatory bowel disease, World Journal of Gastroenterology, vol.15, issue.13, pp.2529-2532, 1998.
DOI : 10.3748/wjg.15.1594

D. H. Present, Is mycophenolate mofetil a new alternative in the treatment of inflammatory bowel disease?, Gut, vol.44, issue.5, pp.592-593, 1999.
DOI : 10.1136/gut.44.5.592

S. Targan, S. Hanauer, and J. Sander, A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor ?? for Crohn's Disease, New England Journal of Medicine, vol.337, issue.15, pp.1029-1064, 1997.
DOI : 10.1056/NEJM199710093371502

D. Present, P. Rutgeerts, and S. Targan, Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease, New England Journal of Medicine, vol.340, issue.18, pp.1398-405, 1999.
DOI : 10.1056/NEJM199905063401804

S. Hanauer, B. Feagan, and G. Lechtenstein, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, The Lancet, vol.359, issue.9317, pp.1541-1550, 2002.
DOI : 10.1016/S0140-6736(02)08512-4

B. Sands, F. Anderson, C. Bernstein, W. Chey, B. Feagan et al., Infliximab Maintenance Therapy for Fistulizing Crohn's Disease, New England Journal of Medicine, vol.350, issue.9, pp.876-85, 2004.
DOI : 10.1056/NEJMoa030815

. Rutgeerts, Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis, New England Journal of Medicine, vol.353, issue.23, pp.2462-76, 2005.
DOI : 10.1056/NEJMoa050516

F. Schnitzler, H. Fidder, M. Ferrante, M. Noman, I. Arijs et al., Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort, Gut, vol.58, issue.4, pp.492-500, 2009.
DOI : 10.1136/gut.2008.155812

S. Hanauer, C. Wagner, M. Bala, L. Mayer, S. Travers et al., Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn???s disease, Clinical Gastroenterology and Hepatology, vol.2, issue.7, pp.542-53, 2004.
DOI : 10.1016/S1542-3565(04)00238-1

P. Rutgeerts, R. Diamond, M. Bala, A. Olson, G. Ichtenstein et al., Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease, Gastrointestinal Endoscopy, vol.63, issue.3
DOI : 10.1016/j.gie.2005.08.011

S. Bell and M. Kamm, Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease, Alimentary Pharmacology and Therapeutics, vol.116, issue.5, pp.501-515, 2000.
DOI : 10.1016/S0016-5085(99)70277-5

S. Vermeire, M. Noman, G. Van-assche, F. Baert, D. Haens et al., Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease, Gut, vol.56, issue.9, pp.1226-1257, 2007.
DOI : 10.1136/gut.2006.099978

L. Toy, E. Scherl, A. Kornbluth, J. Marion, A. Greenstein et al., Complete bowel obstruction following initial response to infliximab therapy for crohn's disease: A series of a newly described complication, Gastroenterology, vol.118, issue.4, p.2974, 2000.
DOI : 10.1016/S0016-5085(00)84412-1

J. Curtis, J. Kramer, C. Martin, K. Saag, N. Patkar et al., Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-?? antagonists, Rheumatology, vol.46, issue.11, pp.1688-93, 2007.
DOI : 10.1093/rheumatology/kem212

J. Cohen, I. Bournerias, V. Buffard, A. Paufler, X. Chevalier et al., Psoriasis induced by tumor necrosis factor-alpha antagonist therapy : a case series, J Rheumatol, vol.34, pp.380-385, 2007.

H. Lee, I. Song, M. Friedrich, A. Gauliard, J. Detert et al., Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-? antagonists, British Journal of Dermatology, vol.176, issue.3, pp.486-91, 2007.
DOI : 10.1002/art.21233

K. Winthrop, Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor, Nature Clinical Practice Rheumatology, vol.52, issue.8, pp.602-612, 2006.
DOI : 10.1038/ncprheum0336

S. Travis, E. Stange, M. Lemann, T. Oresland, Y. Chowers et al., European evidence based consensus on the diagnosis and management of Crohn's disease: current management, Gut, vol.55, issue.suppl_1, pp.16-35, 2006.
DOI : 10.1136/gut.2005.081950b

P. Bach-nga and D. David, Test de détection de la production d'interféron pour le diagnostic des infections tuberculeuses, HAS, 2006.

P. Rutgeerts, G. Van-assche, and S. Vermeire, Review article: infliximab therapy for inflammatory bowel disease - seven years on, Alimentary Pharmacology and Therapeutics, vol.52, issue.1, pp.451-63, 2006.
DOI : 10.1111/j.1365-2036.2005.02405.x

M. Toruner, J. Loftus, W. Harmsen, A. Zinsmeister, R. Orenstein et al., A case control study to identify risk factors for opportunistic infections in patients with inflammatory bowel disease, Gastroenterology, vol.130, p.71, 2006.

J. Reddy, L. Jr, and E. , Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases, Gastroenterology Clinics of North America, vol.35, issue.4, pp.837-55, 2006.
DOI : 10.1016/j.gtc.2006.09.008

A. Mackey, L. Green, L. Liang, P. Dinndorf, and M. Avigan, Hepatosplenic T Cell Lymphoma Associated With Infliximab Use in Young Patients Treated for Inflammatory Bowel Disease, Journal of Pediatric Gastroenterology and Nutrition, vol.44, issue.2, pp.265-272, 2007.
DOI : 10.1097/MPG.0b013e31802f6424

L. Peyrin-biroulet, P. Deltenre, N. De-suray, J. Branche, W. Sandborn et al., Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials, Clinical Gastroenterology and Hepatology, vol.6, issue.6, pp.644-53, 2008.
DOI : 10.1016/j.cgh.2008.03.014

. Hanauer, Human Anti???Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn???s Disease: the CLASSIC-I Trial, Gastroenterology, vol.130, issue.2, pp.323-333, 2006.
DOI : 10.1053/j.gastro.2005.11.030

. Sanborn, Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab, Annals of Internal Medicine, vol.146, issue.12, pp.829-838, 2007.
DOI : 10.7326/0003-4819-146-12-200706190-00159

. Colombel, Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn???s Disease: The CHARM Trial, Gastroenterology, vol.132, issue.1, pp.52-65, 2007.
DOI : 10.1053/j.gastro.2006.11.041

. Sandborn, Adalimumab for Maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut published online 13, Feb Gut, vol.10, 1136.

W. Sandborn, B. Feagan, S. Stoinov, P. Honniball, P. Rutgeerts et al., Certolizumab Pegol for the Treatment of Crohn's Disease, New England Journal of Medicine, vol.357, issue.3, pp.228-266, 2007.
DOI : 10.1056/NEJMoa067594

S. Schreiber, M. Khaliq-kareemi, I. Lawrance, O. Thomsen, O. Hanauer et al., PRECISE 2: Maintenance Therapy with Certolizumab Pegol for Crohn's Disease, N Engl J Med, vol.357, p.1357, 2007.

D. Haens, G. Baert, F. Van-assche, G. Caenepeel, F. Vergauwe et al., A Randomized Comparison of Early Combined Immunosuppression with Conventional Management in Patients with Newly Diagnosed Crohn's Disease, World J Gastroenterol, vol.14, pp.5523-5550, 2008.

F. Gomollón, J. Gisbert, and M. Gassull, Crohnology: A tale of time and times and inflammatory bowel diseases, World Journal of Gastroenterology, vol.14, issue.36, pp.5489-5490, 2008.
DOI : 10.3748/wjg.14.5489

M. Clark, J. Colombel, B. Feagan, R. Fedorak, S. Hanauer et al., American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21???23, 2006, Gastroenterology, vol.133, issue.1, pp.312-351, 2006.
DOI : 10.1053/j.gastro.2007.05.006

L. Peyrin-biroulet, C. Laclotte, X. Roblin, and M. Bigard, Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study, World Journal of Gastroenterology, vol.13, issue.16, pp.2328-2360, 2007.
DOI : 10.3748/wjg.v13.i16.2328

L. Peyrin-biroulet, C. Laclotte, and M. Bigard, Adalimumab maintenance therapy for Crohn???s disease with intolerance or lost response to infliximab: an open-label study, Alimentary Pharmacology & Therapeutics, vol.100, issue.Suppl., pp.675-80, 2007.
DOI : 10.1111/j.1365-2036.2007.03254.x

R. Farrell, M. Alsahli, Y. Jeen, K. Falchuk, M. Peppercorn et al., Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial, Gastroenterology, vol.124, issue.4, pp.917-941, 2003.
DOI : 10.1053/gast.2003.50145

E. Louis, G. Vernier-massouille, and J. Grimaud, Etude STORI infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: interim analysis of a prospective cohort study, 2008.

F. Schnitzler, H. Fidder, M. Ferrante, M. Noman, G. Van-assche et al., LONG-TERM OUTCOME OF TREATMENT WITH INFLIXIMAB IN 440 CROHN'S DISEASE PATIENTS: RESULTS FROM A SINGLE CENTER COHORT, Journal of Crohn's and Colitis Supplements, vol.1, issue.1, p.145, 2007.
DOI : 10.1016/S1873-9954(07)70002-2

F. Baert, M. Noman, S. Vermeire, G. Van-assche, G. Carbonez et al., Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease, New England Journal of Medicine, vol.348, issue.7, pp.601-609, 2003.
DOI : 10.1056/NEJMoa020888

S. Vermeire, M. Noman, G. Van-assche, F. Baert, D. Haens et al., Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease, Gut, vol.56, issue.9, pp.1226-1257, 2007.
DOI : 10.1136/gut.2006.099978

W. Sandborn, B. Feagan, S. Stoinov, P. Honiball, P. Rutgeerts et al., Certolizumab Pegol for the Treatment of Crohn's Disease, New England Journal of Medicine, vol.357, issue.3, pp.228-266, 2007.
DOI : 10.1056/NEJMoa067594

J. Colombel, P. Rutgeerts, W. Reinisch, G. Manttzaris, A. Kornbluth et al., P087 - SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy, Journal of Crohn's and Colitis, vol.3, issue.1, p.1, 2008.
DOI : 10.1016/S1873-9946(09)60114-8

G. Lichtenstein, R. Diamond, C. Wagner, A. Olson, R. Hegedus et al., Infliximab administered as 3-dose induction followed by scheduled maintenance therapy in IBD, Inflammatory Bowel Diseases, vol.14, 2007.
DOI : 10.1097/00054725-200802001-00060

G. Van-assche, G. Paintaud, C. Magdelaine, D. 'haens, G. Baert et al., O08 CONCOMITANT IMMUNOSUPPRESSION DOES NOT IMPACT ON THE OUTCOME OF MAINTENANCE INFLIXIMAB THERAPY IN CROHN'S DISEASE: FINAL RESULTS OF THE IMID TRIAL, Journal of Crohn's and Colitis Supplements, vol.1, issue.1, 2007.
DOI : 10.1016/S1873-9954(07)70010-1

U. Mahadevan, W. Sandborn, D. Li, S. Hakimian, S. Kane et al., Pregnancy Outcomes in Women With Inflammatory Bowel Disease: A Large Community-Based Study From Northern California, Gastroenterology, vol.133, issue.4, pp.1106-1118, 2007.
DOI : 10.1053/j.gastro.2007.07.019

S. Travis, European evidence based consensus on the diagnosis and management of Crohn's disease: current management, Gut, vol.55, issue.suppl_1, pp.16-35, 2006.
DOI : 10.1136/gut.2005.081950b

E. Ehrenpreis, S. Kane, and L. Cohen, Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial, Gastroenterology, vol.117, issue.6, pp.149-150, 2002.
DOI : 10.1016/S0016-5085(99)70276-3

J. Cosnes, L. Beaugerie, F. Carbonnel, and J. Gendre, Smoking cessation and the course of Crohn's disease: An intervention study, Gastroenterology, vol.120, issue.5, pp.1093-1102, 2001.
DOI : 10.1053/gast.2001.23231

S. Post, M. Betzler, B. Von-ditfurth, G. Schurmann, P. Kuppers et al., Risks of Intestinal Anastomoses in Crohn??s Disease, Annals of Surgery, vol.213, issue.1, pp.37-42, 1991.
DOI : 10.1097/00000658-199101000-00007

F. Michelassi and G. Block, Surgical management of Crohn's disease, Adv Surg, vol.26, pp.307-329, 1993.

J. Williams, W. Wong, D. Rothenberger, and S. Goldberg, Recurrence of Crohn's disease after resection, British Journal of Surgery, vol.25, issue.1, pp.10-19, 1991.
DOI : 10.1002/bjs.1800780106

M. Karoui, Traitement chirurgical de la maladie de Crohn, Service de chirurgie générale et digestive, 2004.

I. Arnott, D. Mcdonald, A. Williams, and S. Ghosh, Clinical use of Infliximab in Crohn's disease: the Edinburgh experience, Alimentary Pharmacology and Therapeutics, vol.109, issue.10, pp.1639-1685, 2001.
DOI : 10.1111/j.1572-0241.2000.02349.x

R. Cohen, J. Tsang, and S. Hanauer, Infliximab in Crohn's disease: first anniversary clinical experience, The American Journal of Gastroenterology, vol.14, issue.12, pp.3490-3497, 2000.
DOI : 10.1111/j.1572-0241.2000.01779.x

M. Doubremelle, A. Bourreille, F. Zerbib, D. Heresbach, E. Metman et al., Treatment of Crohn's disease with anti-tnf alpha antibodies (infliximab): results of a multicentric and retrospective study, Gastroenterology, vol.26, pp.973-79, 2002.

S. Hanauer, P. Rutgeerts, and D. , Delayed hypersensibility to infliximab re-infusion after a 2-4 year interval without treatment, Gastroenterology, vol.116, p.731, 1999.